What are the latest advances in CAR T therapy?

During the 2nd European CAR T Cell Meeting in Sitges, ES, the Multiple Myeloma Hub was delighted to speak to Carl June from Perelman School of Medicine, Philadelphia, US. We asked: What are the latest advances in CAR T therapy?

Carl June discusses the benefits of CAR T-cell therapy in patients with multiple myeloma. He speaks about the associated costs of standard therapy vs CAR T and is hopeful that future CAR T developments will drive down costs

[lifeandamyloidosis]

I agree with all you say. I would add that the cost of therapies is however inflated by numerous systems that accept these inflated costs. I find it awkward to mention that us Multiple Myeloma patients, some who can not work, cost the system a million of dollars. I don't know that that is an appropriate calculation of costs. My oncologists and other specialists have revenus of half a million per year, our therapies are bought and sold for half a million dollars and we should shoulder an economic equation that equals a million dollars. I don't agree with that math. I don't know if I am clear in my comment. I worked all my life and I am raising two children and taking care of others...where does that fit in - in the calculation of costs? I don't agree with CAR T costs, or Velcade costs or whatever...they are inflated.